Hamps Bio Limited is set to launch its initial public offering (IPO) from December 13 to December 17, 2024, aiming to raise approximately ₹6.22 crores. The company specializes in the marketing and distribution of pharmaceutical products, including tablets, syrups, and nutritional supplements, through a network of over 50 distributors and e-commerce platforms. The IPO is priced at ₹51 per equity share, with a minimum lot size of 2,000 shares.
₹45.9
₹51
₹96.90
Expert Opinions
Market sentiment for the Hamps Bio IPO is cautiously optimistic, reflecting growing interest in the healthcare and pharmaceutical sectors. Company strengths include a diverse product portfolio, offering over 180 pharmaceutical and nutritional products marketed through a robust distribution network of more than 50 distributors and e-commerce platforms.
However, risks and challenges include potential regulatory hurdles and competition within the crowded pharmaceutical market, which could impact profitability. The valuation analysis sets the IPO price at ₹51 per share, aiming to raise approximately ₹6.22 crores, primarily for purchasing plant and machinery and enhancing brand visibility. From a long-term investment perspective, Hamps Bio is well-positioned to capitalize on the increasing demand for healthcare products in India.
Investor Considerations
Investors considering the Hamps Bio IPO should take into account several key factors. Company performance and fundamentals are encouraging, with a revenue growth of 16.41% and a profit after tax increase of 39.47% from FY23 to FY24, indicating strong operational efficiency. The sector outlook for pharmaceuticals and FMCG is positive, driven by increasing health awareness and demand for nutritional products in India.
The IPO valuation is set at ₹51 per share, aiming to raise approximately ₹6.22 crores, primarily for purchasing plant and machinery and enhancing brand visibility. Growth prospects are strong as the company plans to expand its product offerings and distribution channels. However, risk factors include competition in the crowded pharmaceutical market and regulatory challenges that could impact operations. A long-term investment horizon is advisable, as Hamps Bio is well-positioned to capitalize on the growing demand for healthcare products, making it an attractive option for investors seeking exposure to this sector.
| Date | GMP | Trend |
|---|---|---|
| 19 Dec 2024 18.16 | ₹45.9 | --- |
| 18 Dec 2024 11.54 | ₹45.9 | --- |
| 17 Dec 2024 12.17 | ₹45.9 | Up |
| 16 Dec 2024 17.54 | ₹40 | --- |
| 15 Dec 2024 13.25 | ₹40 | --- |
| 14 Dec 2024 17.24 | ₹40 | Up |
| 13 Dec 2024 11.23 | ₹20 | --- |
| 12 Dec 2024 12.50 | ₹20 | Up |
| 11 Dec 2024 12.13 | ₹00 | --- |
FAQs
The Grey Market Premium showed perfect accuracy in predicting Hamps Bio’s listing performance. The GMP of ₹45.90 predicted a premium of 90% over the issue price, and the stock delivered exactly the same gain of 90%. With zero prediction error, the GMP perfectly captured both the direction and magnitude of the listing gains, demonstrating exceptional precision in this case.
Hamps Bio IPO Current GMP is ₹45.9.
Hamps Bio IPO Expected Returns is 90.00%.
Hamps Bio IPO estimated listing price is ₹96.9.